X T L Biopharmaceuticals reported $706K in Selling and Administration Expenses for its fiscal quarter ending in December of 2024.





Selling And Administration Expenses Change Date
Alaunos Therapeutics USD 447K 138K Mar/2026
Bioline Rx USD 858K 257K Mar/2026
Teva Pharmaceutical Industries USD 1000M 120M Mar/2026
X T L Biopharmaceuticals USD 706K 50K Dec/2024